This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over this hallucinogenic drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.
25I-NBOMe may be used on its own or in combination with other substances, including other psychoactive substances. Analysis of various seized and collected products has shown that the composition of the products can differ and the user is unlikely to be aware of the exact dose or compound(s) present.

Detections reported by the Member States to the Early Warning System have highlighted that 25I-NBOMe may also be encountered in liquid or powdered form. These physical forms may affect the potential for acute toxicity as well as the clinical profile thereof. For example, due to its 8 high potency, nasal insufflation of powdered 25I-NBOMe may increase the risk of (serious) adverse events.

In addition to the manifestation of psychoactive effects commonly observed with serotonergic hallucinogens (e.g. LSD, psilocybin or 2C-B (2,5-dimethoxy-4-bromophenethylamine)), clinical case reports also indicate the potential for inducing severe agitation, confusion and a significant stimulant effect which may also be associated with serotonergic toxicity (serotonin syndrome).

Reported street names include: ‘25I’, ‘dots’, ‘legal acid’, ‘solaris’, ‘cimbi-5’, ‘NBomb’, ‘NEBOME’, ‘smiles’, ‘INBMeO’, ‘BOM-CI’, ‘Hoffman’ and ‘N-boom’.